Conferences
28 March 2019, Royal Society of Chemistry at Burlington House, London, UK
Integrin Targeted Drug Discovery
Synopsis
Integrins are heterodimeric, transmembrane receptors that function in cell adhesion and signalling. They are central to many disease states, including cancer, thrombosis, multiple sclerosis and Crohn’s disease. Integrin targeted therapeutics have been under investigation for some time, but few compounds have made it to / remained on the market due to side effects or lack of efficacy. Given the more recent structural insights, better understanding of downstream pathways, and potential application to a range of therapeutic areas, there has been a resurgence of interest in integrin inhibitors. This symposium will bring together researchers in this area to provide both a historical overview of the area and recent progress in designing the next generation of integrin inhibitors.
Who should attend
Scientists from industry and academia, including medicinal and computational chemists.
Features of the Meeting
Therapeutic targets for integrins
Targeting different RGD recognising integrins
Drug discovery, medicinal chemistry and structure-based design
Plenary speakers, poster session and trade exhibition
Call for Posters
Applications for poster presentation are welcomed. Posters will be displayed throughout the day, and the closing date is 31st December.
Confirmed Speakers
The full programme is available, and confirmed speakers are:
Challenges in integrin antagonist discovery - lessons learnt from GPIIb/IIIa antagonists
Prof Dermot Cox, Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland
New beta-lactam derivatives modulate cell adhesion and signaling mediated by RGD-binding and leukocyte integrins
Prof Daria Giacomini, Chemistry, University of Bologna
Integrins as therapeutic targets: a superficial, but non-trivial family
Dr Simon Goodman, formerly of Preclinical Oncology, Merck Serono
Design of highly potent selective ligands for RGD recognizing integrin subtypes and their application in medicine
Prof Dr Horst Kessler, Chemistry, Technical University of Munich
New strategies to improve the efficacy of small molecule integrin antagonists
Dr Helen Sheldrake, Cancer Therapeutics, University of Bradford
Discovery of novel integrin inhibitors
Thomas McInally, University of Nottingham, UK
Succinimide-based conjugates improve isoDGR cyclopeptide affinity to avß3 without promoting integrin allosteric activation
Giovanna Musco, San Raffaele Hospital Milan, Italy
Integrin avß6-specific peptide-drug conjugates provide a novel and effective therapy for pancreatic cancer
Kate Moore, Barts Cancer Institute, UK
Metadynamics-inspired discovery of cyclic pentapeptides as selective avß6 integrin ligands
Luciana Marinelli, University of Naples, Italy
Registration
Registration is open: discounted rates are available for students and RSC members. In addition, a number of student bursaries are available for post-graduate students.
Exhibition
A relevant trade exhibition will add value to the symposium. The exhibition will be held in the same room as the catering (refreshments and lunch) and posters, and the exhibition package will include:
- chair and table
- electrical access and wi-fi access
- one full delegate attendance.
A delegate pack insert may be booked at £175 - no more than two pages of A4 fixed together.
Venue and Travel
The symposium will be held in the Science and Fish Rooms, Royal Society of Chemistry at Burlington House, Piccadilly, London, W1J 0BA, UK.
Situated in central London, the RSC is easily accessible by public transport, and close to Green Park tube station.
Sponsors
Sponsors are encouraged to support this event, which will help us to offer inexpensive registration fees to young chemists.
Keywords
Heterodimeric receptors
Transmembrane receptors
Drug discovery
Therapeutic targets
Integrins
Integrin inhibitors
